Pavan Bachireddy remembers the moment his team saw the same off-the-shelf CAR T cell therapy work dramatically differently in two patients at MD Anderson Cancer Center in Houston. One patient’s cancer shrank. The other saw no benefit. That puzzle drove a new study that’s now helping explain why.
CAR T cell therapy is a powerful form of cancer treatment that supercharges immune cells to hunt down cancer. Most current therapies are custom-made from a patient’s own cells — a slow, costly process. Off-the-shelf versions, made from healthy donor cells, could be ready in days, not weeks, and help many more people. But so far, they haven’t worked consistently. Now, Bachireddy and his team have found two key reasons: the patient’s immune system and the quality of the donor cells.
The study, published in Cancer Discovery, followed patients with aggressive B-cell lymphoma who received an experimental therapy called cemacabtagene ansegedleucel, or cema-cel. Using advanced tracking methods, researchers watched what happened to the donor CAR T cells after infusion. They discovered that some patients had immune cells already primed to attack the donor cells — like a body rejecting a transplant. These patients showed poor CAR T cell expansion, meaning the therapy couldn’t gain momentum to fight cancer.
But in patients where the CAR T cells multiplied and lasted, two things stood out. First, there was little sign of immune rejection. Second, the donor cells themselves were more "fit" — a biological edge that helped them survive, grow, and destroy cancer. This fitness wasn’t random. Certain CAR T cell populations consistently performed better across different donors and disease types, suggesting a pattern that could be harnessed.
The findings matter because how well CAR T cells expand after infusion is strongly linked to whether a patient improves. Now, researchers can use this knowledge to screen patients ahead of time for immune traits that might lead to rejection. They can also guide manufacturers to select better donor cells and tweak production methods to enrich for the fittest CAR T cells.
"One of the biggest questions in the field has been why the same off-the-shelf CAR T cell therapy can lead to dramatically different results in different patients," said Bachireddy, assistant professor at MD Anderson and scientific director of the ECLIPSE platform. "By identifying both patient and CAR T cell characteristics that influence treatment response, we've uncovered insights that could help us develop more effective therapies for the future."
This isn’t just about one therapy or one cancer. The principles of immune compatibility and cell fitness could shape the next generation of off-the-shelf immunotherapies. For patients waiting for faster, more accessible treatments, that future is coming into focus.